Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
XKDCT-293 in Breast Cancer: NCT06724835 Clinical Landscape Report 2026
15 October 2026
NCT06724835 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Metastatic Renal Cell Carcinoma: NCT06730932 Clinical Landscape Report 2026
15 October 2026
NCT06730932 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lorigerlimab in Platinum-Resistant Fallopian Tube Carcinoma: NCT06730347 Clinical Landscape Report 2026
15 October 2026
NCT06730347 clinical landscape for Platinum-Resistant Fallopian Tube Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Eribulin mesylate in Triple Negative Breast Cancer: NCT06731153 Clinical Landscape Report 2026
15 October 2026
NCT06731153 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
B1962 in Hepatocellular Carcinoma: NCT06724263 Clinical Landscape Report 2026
15 October 2026
NCT06724263 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Everolimus in Advanced Renal Cell Carcinoma: NCT06730672 Clinical Landscape Report 2026
15 October 2026
NCT06730672 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axitinib in Metastatic Renal Cell Carcinoma: NCT06726421 Clinical Landscape Report 2026
15 October 2026
NCT06726421 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PRJ1-3024 in Metastatic melanoma: NCT06727630 Clinical Landscape Report 2026
15 October 2026
NCT06727630 clinical landscape for Metastatic melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Netupitant/Palonosetron Hydrochloride in Endometrial Carcinoma: NCT06726291 Clinical Landscape Report 2026
15 October 2026
NCT06726291 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ESG-401 in Triple Negative Breast Cancer: NCT06732323 Clinical Landscape Report 2026
15 October 2026
NCT06732323 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Advanced Triple-Negative Breast Carcinoma: NCT06735131 Clinical Landscape Report 2026
15 October 2026
NCT06735131 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Alrizomadlin in Neurofibrosarcoma: NCT06735820 Clinical Landscape Report 2026
15 October 2026
NCT06735820 clinical landscape for Neurofibrosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.